Patients with advanced heart failure (HF) have poor prognosis and severe impairment of quality of life.1,2 Improving their treatment is a major unmet need.3 In this issue of the Journal,… Click to show full abstract
Patients with advanced heart failure (HF) have poor prognosis and severe impairment of quality of life.1,2 Improving their treatment is a major unmet need.3 In this issue of the Journal, the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) provides a consensus statement on the pharmacology, indications and unmet needs regarding inotropic agents in patients with advanced HF, focusing also on palliative care and end-of-life aspects.4
               
Click one of the above tabs to view related content.